Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Non-Current Assets (2019 - 2026)

Atea Pharmaceuticals' Non-Current Assets history spans 8 years, with the latest figure at $3.9 million for Q1 2026.

  • Quarterly Non-Current Assets fell 38.0% to $3.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Mar 2026, up 25.83% year-over-year, with the annual reading at $4.2 million for FY2025, 82.75% up from the prior year.
  • Non-Current Assets came in at $3.9 million for Q1 2026, down from $4.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $6.8 million in Q3 2025 to a low of $2.3 million in Q4 2024.
  • The 5-year median for Non-Current Assets is $4.6 million (2022), against an average of $4.8 million.
  • Year-over-year, Non-Current Assets skyrocketed 1083.23% in 2022 and then crashed 48.75% in 2024.
  • Atea Pharmaceuticals' Non-Current Assets stood at $5.8 million in 2022, then decreased by 22.0% to $4.5 million in 2023, then plummeted by 48.75% to $2.3 million in 2024, then surged by 82.75% to $4.2 million in 2025, then dropped by 8.23% to $3.9 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Non-Current Assets are $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $6.8 million (Q3 2025).